You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
CEO David King said that the acquisition of Sequenom positions LabCorp as a leader in NIPT, women's health, and reproductive genetics.
The Chinese firm is also developing a menu of extraction-free molecular diagnostic tests using a proprietary "one-step" reagent.
The company also reported FY2016 revenues rose 5 percent year over year, despite a dip in product revenues for the year.
The researchers also plan to analyze how payors make coverage decisions for NGS-based gene panels, exome, and whole-genome sequencing clinical tests.
Despite recent bills that argue the advent of NIPS will increase abortion, researchers say that there is not yet enough data.
The test detects chlamydia, gonorrhea, and trichomonas from a single patient sample.
The new platform, called Fusion, is an addition to the Panther system and will run qPCR assays with three "mini panels" currently in the works.
The findings, published last week, have prompted Belgian medical genetics centers to routinely report maternal incidental findings from NIPT.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
Last week, the G-BA, a committee that decides about reimbursable medical services in Germany, said it will start a methods evaluation of noninvasive prenatal testing.
The firm sees the new panel as an important step forward in its strategy to further penetrate the molecular diagnostics market with its qPCR products.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
The company said it planned to launch version 3 of Panorama this year during a conference call discussing its second quarter 2016 performance.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Unilabs has licensed the rights to develop, validate, and run Natera's Panorama NIPT technology out of its own laboratories.
Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.
Although Sequenom had garnered support from a diverse range of groups who wanted clarity on patent eligibility, the Supreme Court denied the petition.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
The company has been quietly working on a fully automated NIPT for trisomies 21, 13, and 18 that requires neither next-gen sequencing nor microarray technology.